Pulmonx Corporation LUNG
1.91
0.01
0.53%
as of 25 Sep
- Market cap
- $81.6M
- P/E
- 0.0×
Follow LUNG
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(73.73%) | (77.19%) | (86.22%) | (88.87%) | |
| (37.13%) | (36.97%) | (39.31%) | (36.74%) | ||
ROIC |
(175.58%) | (158.98%) | (153.90%) | (141.03%) | |
Return on Tangible Assets |
(62.50%) | (64.41%) | (70.10%) | (69.12%) | |
Average Days of Receivables |
54.94 | 48.69 | 44.64 | 51.12 | |
Free Cash Flow per Share |
(0.80) | (0.81) | (0.70) | (0.72) | |
Free Cash Flow |
(32.57) | (32.83) | (29.41) | (30.67) | |
Capital Expenditures |
(0.55) | (0.45) | (0.16) | (0.11) | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(18.41%) | (20.10%) | (20.20%) | (23.02%) | |
Accounts Receivable Turnover |
7.20 | 7.18 | 7.14 | 6.21 | |
Accounts Payable Turnover |
4.45 | 6.04 | 5.60 | 3.57 | |
Inventory Turnover |
1.47 | 1.43 | 1.31 | 1.23 | |
Average Days of Payables |
95.74 | 61.02 | 58.42 | 85.05 | |
Days of Inventory on Hand |
242.30 | 247.60 | 274.29 | 298.18 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
20.63% | 21.54% | 22.17% | 22.14% | |
Selling, General and Administrative Expense of Revenue |
115.05% | 111.95% | 112.10% | 107.87% | |
Share Based Compensation of Revenue |
24.56% | 23.46% | 22.31% | 19.72% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.56 | 0.60 | 0.55 | 0.64 | |
Depreciation/Fixed assets |
0.18 | 0.33 | 0.44 | 0.57 | |
Capex/Depreciation |
(1.23) | (0.62) | (0.18) | (0.10) | |
Revenue per Share |
2.24 | 2.22 | 2.11 | 2.06 | |
Operating CF per Share |
(0.78) | (0.80) | (0.70) | (0.72) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(61.91%) | (59.67%) | (60.09%) | (55.03%) |
Columns are period end dates